California University of Science and Medicine Celebrates 2025 MD Match Day California University of Science and Medicine (CUSM) proudly announced that its 2025 MD graduating class successfully secured residency placements as part of the national Match Day event. This milestone…
FDA Approves Alnylam’s AMVUTTRA® for ATTR-CM Treatment Alnylam Pharmaceuticals, Inc., a pioneer in RNAi therapeutics, has announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for its RNAi-based therapeutic, AMVUTTRA® (vutrisiran). This…
Poxel Reports Positive Preclinical Results for PXL065 in HCM POXEL SA, a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for chronic and serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders, has announced positive…
Verastem Oncology Q4 & Full-Year 2024 Results, Business Updates Verastem Oncology, a biopharmaceutical company dedicated to developing innovative therapies for cancer patients, has announced its financial results for the fourth quarter and full year ending December 31, 2024, along with…
NeuroSense Therapeutics Advances Toward Early Canadian Commercialization of ALS Drug NeuroSense Therapeutics Ltd. has announced significant progress toward the early commercialization of PrimeC in Canada. According to a Form 6-K filed with the SEC this morning, Health Canada has invited…
Cardurion Pharmaceuticals Appoints Karen Lewis as Chief People Officer, Strengthening Leadership Amid Growth Cardurion Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on discovering and developing new therapeutic approaches for cardiovascular diseases, has announced the appointment of Karen Lewis as Chief…
Kairos Pharma Publishes Breakthrough on Overcoming Drug Resistance in NSCLC Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, has announced a significant breakthrough in addressing drug resistance to EGFR-targeted therapies for non-small cell lung cancer (NSCLC). A recent peer-reviewed publication in…
InnoCare Doses First Patient in Phase III Trial of ICP-488 for Psoriasis in China InnoCare Pharma, a leading biopharmaceutical company dedicated to developing innovative treatments for cancer and autoimmune diseases, has announced a significant milestone in its clinical development efforts.…
BPGbio to Present Novel E2-Based TPD Program at 5th Annual Summit BPGbio, Inc., a leading biology-first, AI-powered, clinical-stage biopharmaceutical company focused on mitochondrial biology and protein homeostasis, has announced its participation in the 5th Annual Targeted Protein Degradation (TPD) and…
MiNA Therapeutics Adds Norbert Bischofberger to Board, Bríd Ryan as CSO MiNA Therapeutics Limited, a leader in the development of small activating RNA (RNAa) therapeutics, has announced key leadership changes to strengthen its scientific and strategic capabilities. The company has…
Triastek announced that on February 27, 2025, its proprietary 3D-printed non-vitamin K antagonist oral anticoagulant (NOAC) product, T20G, received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA). This milestone follows the product’s prior IND clearance…
Scholar Rock Presents Comprehensive Phase 3 SAPPHIRE Trial Data at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference Scholar Rock, a late-stage biopharmaceutical company committed to advancing groundbreaking treatments for neuromuscular diseases, cardiometabolic disorders, and other serious conditions influenced…
